Online Program Home
  My Program

All Times EDT

* = applied session       ! = JSM meeting theme

Activity Details

238 * ! Wed, 8/11/2021, 10:00 AM - 11:50 AM Virtual
Addressing Nonproportional Hazards Issues in Oncology Clinical Trial Design — Topic-Contributed Papers
Biopharmaceutical Section, Biometrics Section, Statistics and Pharmacometrics Interest Group
Organizer(s): Revathi Ananthakrishnan, Bristol-Myers Squibb; Daniel Li, Bristol-Myers Squibb
Chair(s): Daniel Li, Bristol-Myers Squibb
10:05 AM New alternative measures to hazard ratio
HAJIME UNO, Dana-Farber Cancer Institute
10:25 AM Max-Combo Test for Time-to-Event Endpoints Under Nonproportional Hazards
Ray Lin, Genentech
10:45 AM Design for Immuno-Oncology Clinical Trials with Nonproportional Hazards Patterns
ZHENZHEN XU, FDA; Bin Zhu, National Cancer Institute; YONGSOEK PARK, University of Pittsburg
11:05 AM A 5-Step Stratified Testing and Amalgamation Routine
Rachel Marceau West, Merck & Co. ; Devan V Mehrotra, Merck & Co., Inc.
11:25 AM Discussant: Kay Tatsuoka, Bristol Myers Squibb
11:45 AM Floor Discussion